Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC By Ogkologos - July 9, 2025 716 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Pemigatinib February 1, 2021 Benefit of Adjuvant Capecitabine After Curative Resection of Biliary Tract Cancer... April 6, 2022 Analysis of the Gut Microbiome Provides Clues to Survival Following Nivolumab... July 9, 2021 Can Using Hair Dyes or Hair Relaxers Impact Your Cancer Risk? July 13, 2023 Load more HOT NEWS FDA Grants Accelerated Approval to Elranatamab-bcmm for Multiple Myeloma EMA Recommends Extension of Therapeutic Indications for Selinexor Starving cancer into submission Opinion: ‘The UK must be more ambitious than just clearing the...
